DolPHIN2

Search

  • About DolPHIN 2
  • Research
    • Clinical trial
    • Qualitative research
    • Health Economics
    • Community Voices
  • Resources
  • News & Events
    • News
    • Events
    • Past events

Mother-to-child transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.

image source: pexels

The DolPHIN 2 programme investigates the safe and effective use of dolutegravir for women who present with untreated HIV in late pregnancy

The team at the Infectious Diseases Institute, Kampala

DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.

0

How we work

About DolPHIN 2

Read about the challenges that the DolPHIN 2 project seeks to address and why.

The DolPHIN 2 Consortium

Learn more about our multinational research consortium, comprising partners in Europe and sub-Saharan Africa.

Community Voices

Collaboration with the community is at the heart of DolPHIN 2. Click here to learn more about our community engagement, and to hear from some of our study participants.
1

Resources

10 Mar 2021

DolPHIN2 Infographic

The DolPHIN 2 Clinical Trial is designed to yield high-quality evidence on the efficacy and safety of dolutegravir in late presenting pregnant women, to allow definitive recommendations for use of dolutegravir to reduce MTCT in this high-risk scenario.  

Video
03 Dec 2019

HIV on Trial

Meet our research team, hear from some of our research participants and learn more about the DolPHIN story so far.

Video
28 Nov 2019

They become strong when they see me doing this

Jackie Kyeyune, a peer mother living with HIV, discusses how she uses her lived experience to support and inspire the DolPHIN 2 trial participants. 

Video
28 Nov 2019

Trial Management at the Ugandan site

Dr Kenneth Kintu, trial manager at the IDI site, discusses the challenges and rewards of the study, and his hopes for the future

Video
View all Resources
1

News

The Ugandan Team Celebrates World Breastfeeding Week

08 Aug 2019

DolPHIN-2 presents primary outcome analysis at CROI 2019

05 Mar 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

WHO released a statement on 18 May 2018 relating to a potential safety issue affecting women living with HIV using dolutegravir at the time of conception.

20 Jun 2018
View all News and Events

@UoLDolPHIN2 on Twitter

RT @At_The_EQUATOR: #WorldBreastfeedingWeek2022 Breast milk is the best choice for the baby and the mother. Fathers have to step up and support their #breastfeeding partners. #BreastfeedingWeek #WBW2022 #BreastMilkDonation #educateandsupport @cgbanda @paulkgonza @livuninews @wellcometrust @okoboi25 https://t.co/dzIocX3nZe
6 days 17 hours ago
RT @drlaurajwaters: #AIDS2022 @CatrionaWaitt summarising optimal DTG use in women - they key is COMMUNICATION & ONGOING DIALOGUE. Hell yes to that! This is a great slide https://t.co/zyWiuM1pBY
1 week 1 day ago
RT @CatrionaWaitt: @AIDS_conference #AIDS2022 @agenceANRS @UNITAID @UoLDolphin2 @modernart4sa exhibition in Global Village. Bringing art and film to creatively engage on many HIV related topics. The leaflets are great - come and visit! https://t.co/2PS2QWa8jP
1 week 2 days ago
RT @CatrionaWaitt: I am looking forward to attending this in person. Colleagues on Twitter - online option here @JacquelineKyey1 @SemakulaRitah @JoviaMirembe6 @SeniorCymo @fwojara @UoLDolphin2 @MagoolaJohnson @IDIMakerere https://t.co/IUNW62pLlI
1 week 2 days ago
Read about the Trio pooled data analysis that DolPHIN2 contributed to @LivUniISMIB @LSTMnews @IDIMakerere @EpiBiostats_UCT @radboudumc https://t.co/FYHQzFpDnV
1 week 2 days ago
RT @TRIO_ARToptim: Thank you very much to joined @TRIO_ARToptim during the satellite symposium @AIDS_conference @UNITAID @WHO @ezintsha @LivUni @agenceANRS @SiteAnrsCamroun @UoLDolphin2 @transvihmi https://t.co/w4IHcCPLHU
1 week 2 days ago
RT @TRIO_ARToptim: TRIO SYMPOSIUM Move to session 2: Community engagement @TRIO_ARToptim @AIDS_conference @UNITAID @WHO @ezintsha @LivUni @agenceANRS @SiteAnrsCamroun @UoLDolphin2 @transvihmi #AIDS2022 https://t.co/c1qovLraGB
1 week 2 days ago
RT @TRIO_ARToptim: LIVE ! TRIO Symposium Treatment Optimisation: lessons from TRIO- ADVANCE, DOLPHIN2 AND NAMSAL- ANRS-12313 trial funded by UNITAID @TRIO_ARToptim @AIDS_conference @UNITAID @WHO @ezintsha @LivUni @agenceANRS @SiteAnrsCamroun @UoLDolphin2 @transvihmi #AIDS2022 https://t.co/AIriEyjgV2
1 week 2 days ago
RT @CatrionaWaitt: @TRIO_ARToptim @UNITAID @AIDS_conference symposium is underway! Room 517b/ Channel 4 - join us! https://t.co/ShNvh0G8OB
1 week 2 days ago
TRIO preliminary results currently being presented at #AIDS2022 @LivUniISMIB @LSTMnews @IDIMakerere @EpiBiostats_UCT @radboudumc https://t.co/xd2P0hGlP9
1 week 2 days ago
RT @TamaraTOVARS: LIVE #AIDS2022 - @TRIO_ARToptim partners meeting @AIDS_conference and preparing last details of the satellite symposium “Lessons learned form TRIO - ADVANCE, DolPHIN2 and NAMSAL-ANRS-12313 trials” @UNITAID @WHO @LivUni @ezintsha @agenceANRS @SiteAnrsCamroun https://t.co/VVyKa3Istt
1 week 3 days ago
RT @TRIO_ARToptim: Counting hours till @TRIO_ARToptim satellite symposium @AIDS_conference - join us tomorrow 30/07 at 8am - room 517c/Channel 4 @UNITAID @WHO @ezintsha @LivUni @agenceANRS @SiteAnrsCamroun @UoLDolphin2 @transvihmi #AIDS2022 https://t.co/WaGZUvCNIf
1 week 3 days ago

The D2 Consortium

The DolPHIN 2 consortium is a multinational partnership comprising five research organisations and our funder, Unitaid.

University of Liverpool

Liverpool School of Tropical Medicine

Infectious Diseases Institute

University of Cape Town

Radboud University Medical Centre

Unitaid

Contact us

dolphin [dot] admin [dot] team [at] liverpool [dot] ac [dot] uk

ClinicalTrials.gov Identifier: NCT03249181

Follow us

  • Twitter
A Remora website by Manta Ray Media